Risk of hepatitis B virus reactivation and its effect on survival in advanced hepatocellular carcinoma patients treated with hepatic arterial infusion chemotherapy and lenvatinib plus programmed death receptor-1 inhibitors.

Authors:
Yang Z; Guan R; Fu Y; Hu D; Zhou Z and 2 more

Journal:
Front Cell Infect Microbiol

Publication Year: 2024

DOI:
10.3389/fcimb.2024.1336619

PMCID:
PMC10896825

PMID:
38415009

Journal Information

Full Title: Front Cell Infect Microbiol

Abbreviation: Front Cell Infect Microbiol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Communicable Diseases

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflict of interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."

Evidence found in paper:

"The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work is funded by the Guangdong Basic and Applied Basic Research Foundation (2022A1515110961), Guangzhou Science and Technology Plan Project (2023A04J2125), and National Natural Science Foundation of China (No: 82103566 and 82303893)."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025